Gastrointestinal Stromal Tumor (MSK, NPJ Precis Oncol 2023)

Summary

Gastrointestinal Stromal Tumor (MSK, NPJ Precis Oncol 2023) is a study catalogued by cBioPortal DataHub under the cancer-type code gist. EvidenceHelix groups it with sarcoma and soft tissue studies.

Study description

Paired analysis of 499 Gastrointestinal stromal tumor/normal pairs via MSK-IMPACT platform.

Text as published in the source's study metadata.

Citation & PubMed

Diana et al. NPJ Precis Oncol 2023

Linked PubMed records: PMID 36593350

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

gist_msk_2022

Short name

Gastrointestinal Stromal Tumor (MSK, NPJ Precis Oncol 2023)

Source cancer-type code

gist

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Diana et al. NPJ Precis Oncol 2023

• PubMed record 36593350 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Gastrointestinal Stromal Tumors (MSK, Clin Cancer Res 2023)

  Targeted sequencing of 469 gastrointestinal stromal tumors and their matched normals via MSK-IMPACT.

  Sarcoma and soft tissueMSK studiesSource code gistPubMed 1

• Ewing Sarcoma (MSK, Cancer Research 2024)

  Targeted Sequencing of 277 Ewing sarcoma and Desmoplastic small round cell patient tumors with their matched normal pairs via MSK-IMPACT platform to detect EWSR1 chromoplexy-associated structural rearrangements.

  Sarcoma and soft tissueMSK studiesSource code esPubMed 1

• Pediatric Rhabdomyosarcomas (MSK, JCO Precis Oncol 2023)

  Targeted sequencing of 24 cases with extremity rhabdomyosarcoma tumors and their matched normals (MSK Cohort) via MSK-IMPACT.

  Sarcoma and soft tissueMSK studiesSource code rmsPubMed 1

• Rhabdomyosarcomas (MSK, NPJ Precis Oncol 2023)

  Sequential targeted sequencing on 20 rhabdomyosarcoma tumors and their matched normals from the MSK cohort using MSK-IMPACT.

  Sarcoma and soft tissueMSK studiesSource code rmsPubMed 1

• Sarcoma (MSK, J Pathol 2023)

  Targeted sequencing of 82 radiation-associated sarcomas and their matched normals via MSK-IMPACT.

  Sarcoma and soft tissueMSK studiesSource code mixedPubMed 1

• Sarcoma (MSK, Nat Commun. 2022)

  Targeted Sequencing of 2138 Sarcoma samples and matched normals via MSK-IMPACT.

  Sarcoma and soft tissueMSK studiesSource code soft_tissuePubMed 1

• Sarcoma (MSKCC/Broad, Nat Genet 2010)

  Sanger-sequenced 226 protein-coding genes (3,849 exons and adjacent intronic) on 207 samples (with 205 matched normals) encompassing 7 major sarcoma subtypes.

  Sarcoma and soft tissueMSK studiesSource code soft_tissuePubMed 1

• Soft Tissue and Bone Sarcoma (MSK, Nat Commun 2022)

  Targeted sequencing of 7,494 soft tissue and bone sarcoma samples using the Foundation Medicine platform.

  Sarcoma and soft tissueMSK studiesSource code soft_tissuePubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.